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ABSTRACT
This study reports the application of inverse virtual screening (iVS) methodologies to identify cellular pro-
teins as suitable targets for a library of heterocyclic small-molecules, with potential pharmacological impli-
cations. Standard synthetic procedures allow facile generation of these ligands showing a high degree of
core scaffold diversity. Specifically, we have computationally investigated the binding efficacy of the new
series for target proteins which are involved in cancer pathogenesis. As a result, nine macromolecules
demonstrated efficient binding interactions for the molecular dataset, in comparison to the co-crystallised
ligand for each target. Moreover, the iVS analysis led us to confirm that 27 analogues have high affinity
for one or more examined cellular proteins. The additional evaluation of ADME and drug score for
selected hits also highlights their capability as drug candidates, demonstrating valuable leads for further
structure optimisation and biological studies.
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1. Introduction
Heterocyclic chemistry is one of the most valuable sources of
novel molecules with a wide range of biological activities, mainly
due to the unique ability of the resulting compounds to mimic
the structure of endogenous ligands and reversibly bind to vari-
ous targets of interest1–3. In medicinal chemistry, the main advan-
tage of heterocyclic structures possibly rely on the capability of
synthesising one such a library based on a specific core, allowing
screening protocols against a variety of different targets4. Fused
heterocycles can also be designed with almost unlimited combina-
tions, resulting in novel bi- or polycyclic scaffolds with diverse
physical, chemical, and biological properties. Overall, the fusion of
rings leads to sterically well-defined and rigid structures, holding
the promise for high functional specialisation which results from
the ability to orient substituents in three-dimensional space as
required by the biological targets5. From cancer therapy to the
treatment of infectious, parasitic, and metabolic diseases, the
drugs employed are often based on biologically active heterocyc-
lic templates that interfere with the functioning of enzymes, the
transmission of nerve impulses or the action of hormones on
receptors, to name a few actions.
Scaffold diversity (i.e. variation of the nature of core scaffolds),
appendage diversity (or building-block diversity, i.e. variation in
structural moieties around a common scaffold), functional group
diversity (i.e. variation in the functional groups present in the
molecules) and stereochemical diversity (i.e. variation in the
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three-dimensional orientation of macromolecule-interacting resi-
dues) are the main determinants for late stage chemical diversifi-
cation6–8. Indeed, it is generally recognised that the more
structurally diverse a molecule is, the more likely it can interact
with a particular biological macromolecule in a selective and spe-
cific manner6,7,9–12. In this context, the exploitation of scaffold
diversity has a strategic role to reach amplified structural variation
and explore new areas of the chemical space in biological investi-
gations9,13–15. Moreover, it has been reported that the overall
shape diversity of small-molecules is primarily dependent on the
nature of the specific molecular scaffold (being the latter also
intrinsically linked to functional diversity)16, with the peripheral
substituents having a lower impact17,18. Therefore, there is a wide-
spread consensus that the increase of scaffold diversity in a small-
molecule library is one of the most effective means to implement
its whole structural diversity6,7,9,13–15.
Computer-aided molecular screening has become a crucial tool
in drug design and discovery and computational techniques rep-
resent a valid resource for the rapid evaluation of new com-
pounds with potential biological activity. Currently, approaches
such as structure-based, ligand-based and virtual screening are
widely used in various drug discovery contexts, spanning from hit
identification to lead optimisation stages19–22. The recognition of
biological targets by synthetic molecules is of primary importance,
as well as the possibility to analyse a big database of compounds
by evaluating their binding mode with targets of pharmacological
interest (i.e. virtual screening)23,24. In contrast, the inverse virtual
screening (iVS) is a computational approach that focuses on the in
silico evaluation of a panel of biological targets typically involved
in diseases25–28. Specifically, multiple cellular proteins (from appro-
priately built databases) are screened by iVS in order to identify
potential targets for suitable ligands of interest. This methodology
allows the rapid analysis of crucial features in the process of hit
identification, including target validation, drug repurposing and
side effects/toxicity prediction. Moreover, iVS demonstrates a valu-
able tool to preliminary explore possible biological activities
towards a selection of protein targets having pharmaco-
logical interest.
Herein we report the in silico investigation of 32 new hetero-
cyclic small-molecules through iVS, in order to validate a scaffold-
guided structural diversity approach for future biological tests.
This compound dataset shows high variation in the nature of the
core molecular scaffolds (i.e. indole, indazole, quinoline, naphtyri-
done, phthalazinone and phthalhydrazide). iVS analysis has been
conducted through a panel of 32 selected proteins implicated in
cancer progression and cancer cell survival18,29,30. The study high-
lights that the majority of compounds have potential to interact
with the examined targets, representing an outstanding starting
point to drive biological evaluation in a rapid and cost-effect-
ive fashion.
2. Results and discussion
2.1. Heterocyclic small-molecule dataset
The dataset of compounds is composed by 32 terms (Table 1)
which have been easily obtained through standard synthetic
methodologies (see Section 1, Supporting Information), in order to
introduce (alkoxy)phenyl- and (halo)phenyl-based residues (typic-
ally recurrent in bioactive agents)31–34 in six heterocyclic scaffolds
(i.e. indazole for 1a–f, indole for 2a–h, quinoline for 3a–d, naph-
tyridone for 4a–j, phthalazinone for 5 and phthalhydrazide 6a–d;
Table 1). The experimental procedures and characterisation data
of all new intermediates and final compounds are reported in
Supporting Information (Section 2).
2.2. Molecular modelling
The compound library was screened in iVS modality against a
panel of 32 cellular targets (Table 1S, Supporting Information),
which have been selected for their association to cancer progres-
sion and survival. This in silico approach allows the prediction of
activity and selectivity through the evaluation of binding energies.
Therefore, a large dataset of compounds can be narrowed to a
defined group of promising candidates for following biological
evaluation. For our purpose, calculations were performed with
Autodock Vina, a validated software for iVS applications29,30.
Docking analysis of crystallised ligands, with an established bind-
ing mode, were carried out in order to obtain a minimum energy
level which has been used as the cut-off for the assessment of
binding energies of the new ligands. In particular, the binding effi-
ciency was evaluated through the ratio between the binding ener-
gies of analysed ligands and reference ligands co-crystallised in
the protein, by applying Equation (1):
d ¼ DGcompound
DGreference ligand
(1)
The values of binding energies have been organised in a
matrix of 32 structures versus 32 selected cellular targets (as
shown in Table 2S, Supporting Information). Each significant result
was manually checked, to avoid odd or impossible interactions.
From the library, compounds showing a d 1 in a particular pro-
tein were selected and further analysed. A mathematical filter was
also applied to the resulting energies as suggested by Bifulco
et al.29,30, in order to overcome the lack of selectivity and occur-
rence of false positives, as well as to avoid systematic errors asso-
ciated with the interaction of ligands and biological targets.
Equation (2) was used to normalise the binding energy values in
the matrix:
V ¼ V0= ML þMRð Þ=2
 
(2)
In this formula, V is the new value associated with each com-
pound, V0 is the value of binding energy obtained from the dock-
ing calculation, ML is the average binding energy of each ligand
(in the different targets) and MR is the average binding energy
associated with each target (for the different ligands). Each single
value in the matrix (Figure 1) represents the interaction between
a single ligand versus a specific cellular protein (Table 3S and
Figure1S–32S, Supporting Information). This was normalised by
simultaneously taking into account the influence of the two spe-
cific averages from Equation (2). The values obtained led to the
selection of various compounds against the different proteins,
highlighting nine targets from the entire collection (i.e. PDB code:
3l3l, 3oyw, 4qmz, 2fb8, 3lbz, 4ks8, 4u5j, 4ual and 5h2u; for corres-
pondence between PDB codes and proteins, see Table 1S,
Supporting information). Specifically, these cellular proteins
showed a higher trend of V values for the compound dataset, in
comparison to the V values of the specific co-crystallised inhibitor.
V values against the selected targets are summarised in Table 2.
Once identified the suitable targets for the library, we focussed
on defining potency and overall binding affinity of the com-
pounds. We used a cut-off of 30% potency to define the most
active compounds for each protein. Interestingly, 27 out of 32
analogues demonstrated to possess high binding energies for one
or more of the nine identified targets (i.e. 3l3l, 3oyw, 4qmz, 2fb8,
3lbz, 4ks8, 4u5j, 4ual and 5h2u). Indeed, some active compounds
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY 45
show high predicted affinity for more than one target, particularly
compound 6d. The lack of selectivity is not always desirable in
drug discovery, although this behaviour could also represent an
advantage (e.g. in the case of improved pharmacological effects
of multi-target drugs)35,36. Therefore, additional mathematical fil-
ters (i.e. ligand efficiency or binding efficiency index) can be
adopted for a more accurate analysis of the calculated selectivity
for each compound. In contrast, five compounds were completely
Table 1. Structures of the heterocyclic small-molecules analysed by iVS screening.
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devoid of activity (i.e. 1a,c, 2d,e and 4j), with regards to the calcu-
lated binding energies. Table 3 resumes the most potent ligands
for each cellular protein.
As previously mentioned, the proteins analysed in this study
play critical roles in tumour events and new binders are regarded
as the potential agents for anti-cancer therapies37–49. Therefore,
we examined literature records in order to cross-validate our
method. Noteworthy, analogues based on the same core scaffolds
have already demonstrated a good profile as inhibitors of the
cellular targets analysed in this study. For instance, it has been
reported that indole-based compounds are inhibitors of serine/
threonine-protein kinase B-raf (BRAF)50,51, B-cell lymphoma 6
(BCL-6)52, proto-oncogene tyrosine-protein kinase Src (c-Src)53,54
and poly (ADP-ribose) polymerase (PARP)55, in clear agreement
with our model. Similarly, indazole-based derivatives have been
reported as inhibitors of BRAF56, phthalazinone core is present in
inhibitors of PARP57, as well as quinoline scaffold is common in
molecules acting as c-Src58 and mammalian sterile20-like protein
kinase 3 (MST3) inhibitors59. These evidences validate our iVS
method in order to enable the identification of suitable targets for
a particular molecular library, foreseeing successful biological
investigation.
2.3. Drug score and ADME assessment
The in silico assessment has been expanded through the evalu-
ation of pharmacokinetic profiles and possible adverse side effects
for the 32 new compounds reported in this study. In the first
instance, we have determined the toxicity risk, the fragment-based
druglikeness and the drug score (see Table 4S, Supporting
Information; data calculated with DataWarrior version 4.7.2)60. The
assessment of toxicity risk aims to locate substructures within the
chemical structure which are indicative of risk within the four
major toxicity classes – i.e. mutagenicity, tumorigenicity, irritating
effects, and reproductive effects. The fragment-based druglikeness
is based on a list of distinct substructure fragments with associ-
ated scores. The druglikeness is calculated summing up score val-
ues of those fragments that are present in the particular molecule
under investigation. The drug score combines druglikeness, cLogP,
LogS, molecular weight, and toxicity risks in one value that may
be used to judge the overall potential of the compound to qualify
Table 2. Results of calculated V values for the analysed biological targets in
the study.
Protein (PDB code)
3l3l 3oyw 4qmz 2fb8 3lbz 4ks8 4u5j 4ual 5h2u
Liganda 0.818 0.569 0.930 1.040 0.739 0.828 0.803 1.046 1.077
1a 1.024 0.919 0.950 1.057 0.880 0.979 0.995 0.986 1.043
1b 0.963 0.939 0.956 1.040 0.861 1.020 0.989 0.969 1.037
1c 0.986 0.914 0.922 1.007 0.863 0.951 0.978 0.959 1.058
1d 0.987 0.755 0.922 1.053 0.900 1.058 1.014 1.016 0.996
1e 1.013 0.933 0.962 1.013 0.894 0.956 0.995 0.986 1.042
1f 0.983 0.782 1.047 1.058 0.910 1.063 1.054 1.076 1.086
2a 1.013 0.945 0.962 1.057 0.930 1.014 1.006 0.997 1.085
2b 0.955 0.955 0.983 1.044 0.914 1.048 1.015 0.994 1.073
2c 0.988 0.797 0.946 1.031 0.876 1.058 1.072 1.060 1.050
2d 0.949 0.909 0.964 1.036 0.858 0.946 0.951 0.999 1.065
2e 0.978 0.918 0.949 1.042 0.880 0.942 1.004 0.973 1.060
2f 1.017 0.928 0.991 1.080 0.890 0.996 0.989 1.034 1.077
2g 1.104 0.824 0.962 1.104 0.981 0.989 1.004 1.133 1.110
2h 1.109 0.909 0.940 1.055 1.007 1.037 1.040 1.008 1.083
3a 1.147 0.963 0.954 0.994 0.897 0.983 1.033 1.067 1.014
3b 1.151 0.953 0.993 0.964 0.926 0.951 0.967 1.059 1.006
3c 1.199 0.927 1.002 1.049 1.000 0.927 1.089 1.067 1.004
3d 1.169 0.874 1.002 1.060 0.912 0.973 0.999 1.090 1.036
4a 1.093 0.807 1.001 1.082 0.872 1.018 1.010 0.978 1.121
4b 1.078 0.884 1.010 1.067 0.884 1.027 1.030 1.053 1.148
4c 1.028 0.792 0.966 1.117 0.910 0.983 1.011 1.103 1.155
4d 1.053 0.784 1.041 1.141 0.889 0.987 1.095 1.016 1.146
4e 1.089 0.884 0.964 1.100 0.859 0.992 1.007 1.053 1.169
4f 1.109 0.866 1.030 1.043 0.929 0.977 1.015 1.006 1.136
4g 1.112 0.965 1.002 1.122 0.853 1.007 1.043 1.055 1.190
4h 1.023 0.863 0.984 0.944 0.967 0.965 1.028 0.961 1.074
4j 0.933 0.776 0.972 1.036 0.766 0.904 0.958 0.962 1.090
5 1.047 0.894 0.951 0.904 0.932 0.921 0.949 1.065 0.958
6a 1.104 0.820 0.954 1.093 0.923 1.006 0.987 1.067 1.057
6b 1.137 0.830 0.941 1.004 0.934 0.970 0.963 1.056 0.862
6c 1.137 0.878 1.005 1.051 0.891 0.964 1.024 1.113 1.132
6d 1.130 0.956 1.042 1.141 1.030 1.000 0.970 1.072 1.114
aco-crystallised ligand in the binding pocket of each protein.
Figure 1. Matrix of results for calculated V values from the iVS analysis.
Table 3. Selected hit compounds for each target.
Protein (PDB code) Compounds
3l3l 2h 3a 3b 3c 3d 4g 6b 6c 6d
3oyw 1b 1e 2a 2b 2f 3a 3b 4g 6d
4qmz 1f 3c 3d 4b 4d 4f 4g 6c 6d
2fb8 2f 2g 4a 4c 4d 4e 4g 6a 6d
3lbz 2a 2h 2g 3c 4f 4h 5 6b 6d
4ks8 1b 1d 1f 2a 2b 2c 2h 4a 4b
4u5j 1f 2c 2h 3a 3c 4b 4d 4g 4h
4ual 1f 2g 3a 3c 3d 4c 6a 6c 6d
5h2u 4a 4b 4c 4d 4e 4f 4g 6c 6d
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as a drug. The results of these calculations for the entire library
propose several compounds with a positive druglikeness and drug
score> 0.3. In particular, 2g, 2h, 4h, 5 and 6d demonstrated
valuable profiles as drug candidate. For the five hits, the ADME
properties were also calculated and the results are reported in
Table 4. The results show that compounds 2g, 2h, 4h, 5 and 6d
exhibit also a good oral bioavailability (i.e. human intestinal
absorption> 95%) and Caco-2 cell permeability >22 nm s1
(Table 4). Although their high plasma protein binding (PPB
>85%), 2h, 4h, 5 and 6d are also supposed to satisfyingly perme-
ate the blood-brain barrier (BBB penetration <1).
3. Conclusions
We have described here the computational evaluation of a newly
synthesised series of 32 heterocyclic small-molecules to explore
molecular diversity and scaffold hopping through iVS approaches.
Standard synthetic procedures allow the ease production of these
compounds which are based on different heterocyclic scaffolds
(i.e. indole, indazole, quinoline, naphtyridone, phthalazinone, and
phthalhydrazide). The increase of scaffold diversity in small-mole-
cules is recognised as an efficient way to implement the structural
variation of molecular libraries, in order to reach specific inter-
action with a particular biological macromolecule.
iVS represents a validated computational tool for the assess-
ment of binding towards targets of pharmacological interest. We
have used this approach to define preliminary evaluation of the
compound dataset versus a panel of cellular proteins involved in
cancer progression and cancer cell survival. In the calculations, the
normalisation of predicted binding energies allows to identify
effective interactions for the compounds with nine biological tar-
gets – i.e. PARP, MST3, BCL6, c-Src, B-Raf kinase, galectin-1, serine/
threonine-protein kinase PAK 6, serine/threonine-protein kinase
MRCK beta, and protein-tyrosine kinase 6. Moreover, this study
highlights a defined set of biological targets relevant for each
active compound, which will drive subsequent bio-
logical screening.
Disclosure statement
The authors declare no conflicts of interest.
References
1. Franzen RG. Recent advances in the preparation of hetero-
cycles on solid support: a review of the literature. J Comb
Chem 2000;2:195–214.
2. Dolle RE, Le Bourdonnec B, Morales GA, et al.
Comprehensive survey of combinatorial library synthesis:
2005. J Comb Chem 2006;8:597–635.
3. Kaushik NK, Kaushik N, Attri P, et al. Biomedical importance
of indoles. Molecules 2013;18:6620–62.
4. Macarron R, Banks MN, Bojanic D, et al. Impact of high-
throughput screening in biomedical research. Nat Rev Drug
Discov 2011;10:188–95.
5. Shi F, Zeng XN, Cao XD, et al. Design and diversity-oriented
synthesis of novel 1,4-thiazepan-3-ones fused with bioactive
heterocyclic skeletons and evaluation of their antioxidant
and cytotoxic activities. Bioorg Med Chem Lett 2012;22:
743–6.
6. Galloway WR, Spring DR. Is synthesis the main hurdle for
the generation of diversity in compound libraries for screen-
ing? Expert Opin Drug Discov 2009;4:467–72.
7. Galloway WRJD, Isidro-Llobet A, Spring DR. Diversity-ori-
ented synthesis as a tool for the discovery of novel biologic-
ally active small molecules. Nat Commun 2010;1:1.
8. Isidro-Llobet A, Murillo T, Bello P, et al. Diversity-oriented
synthesis of macrocyclic peptidomimetics. Proc Natl Acad
Sci USA 2011;108:6793–8.
9. Galloway WRJD, Bender A, Welch M, Spring DR. The discov-
ery of antibacterial agents using diversity-oriented synthesis.
Chem Commun 2009;18:2446–62.
10. Spandl RJ, Bender A, Spring DR. Diversity-oriented synthesis;
a spectrum of approaches and results. Org Biomol Chem
2008;6:1149–58.
11. Lipinski C, Hopkins A. Navigating chemical space for biology
and medicine. Nature 2004;432:855–61.
12. Spring DR. Diversity-oriented synthesis; a challenge for syn-
thetic chemists. Org Biomol Chem 2003;1:3867–70.
13. Burke MD, Berger EM, Schreiber SL. Generating diverse skel-
etons of small molecules combinatorially. Science 2003;302:
613–8.
14. Kennedy JP, Williams L, Bridges TM, et al. Application of
combinatorial chemistry science on modern drug discovery.
J Comb Chem 2008;10:345–54.
15. Shelat AA, Guy RK. Scaffold composition and biological rele-
vance of screening libraries. Nat Chem Biol 2007;3:442–6.
16. Galloway WRJD, Diaz-Gavilan M, Isidro-Llobet A, Spring DR.
Synthesis of unprecedented scaffold diversity. Angew Chem
Int Ed Engl 2009;48:1194–6.
17. Sauer WH, Schwarz MK. Size doesn’t matter: Scaffold diver-
sity, shape diversity and biological activity of combinatorial
libraries. CHIMIA Int J Chem 2003;57:276–83.
18. Sauer WH, Schwarz MK. Molecular shape diversity of com-
binatorial libraries: a prerequisite for broad bioactivity. J
Chem Inf Comput Sci 2003;43:987–1003.
19. Austin ND, Sahinidis NV, Trahan DW. Computer-aided
molecular design: An introduction and review of tools, appli-
cations, and solution techniques. Chem Eng Res Design
2016;116:2–26.
Table 4. In silico ADME profile of selected hits.
Absorptiona Distributiona
Compound HIA (%)b
In vitro Caco-2 cell
permeability (nm s–1) In vitro PPB (%)
In vivo BBB
penetration (Cbrain/Cblood)
2g 96.96 51.63 91.53 1.82
2h 97.50 57.31 92.64 0.79
4h 96.36 25.24 86.88 0.06
5 96.16 22.38 90.14 0.56
6d 97.57 29.13 99.98 0.70
aThe properties related to ADME were predicted using PreADMET web-based application (http://preadmet.bmdrc.kr).
bHuman intestinal absorption (HIA, %).
48 A. CILIBRIZZI ET AL.
20. Floresta G, Amata E, Dichiara M, et al. Identification of
potentially potent heme oxygenase 1 inhibitors through 3D-
QSAR coupled to scaffold-hopping analysis. ChemMedChem
2018;13:1336–42.
21. Greish KF, Salerno L, Al Zahrani R, et al. Novel structural
insight into inhibitors of heme oxygenase-1 (ho-1) by new
imidazole-based compounds: Biochemical and in vitro anti-
cancer activity evaluation. Molecules 2018;23:1209.
22. Salerno L, Amata E, Romeo G, et al. Potholing of the hydro-
phobic heme oxygenase-1 western region for the search of
potent and selective imidazole-based inhibitors. Eur J Med
Chem 2018;148:54–62.
23. Ruiz-Torres V, Encinar JA, Herranz-Lopez M, et al. An
updated review on marine anticancer compounds: The use
of virtual screening for the discovery of small-molecule can-
cer drugs. Molecules 2017;22:1037.
24. Lavecchia A, Di Giovanni C. Virtual screening strategies in drug
discovery: a critical review. Curr Med Chem 2013;20:2839–60.
25. Zhao H, Lin C, Hu K, et al. Discovery of novel estrogen-
related receptor alpha inverse agonists by virtual screening
and biological evaluation. J Biomol Struct Dyn 2018;1–8.
doi:10.1080/07391102.2018.1462736.
26. Xu X, Huang M, Zou X. Docking-based inverse virtual screen-
ing: Methods, applications, and challenges. Biophys Rep
2018;4:1–16.
27. Song Y, Xue X, Wu X, et al. Identification of n-phenyl-2-(n-
phenylphenylsulfonamido)acetamides as new RORc inverse
agonists: virtual screening, structure-based optimization, and
biological evaluation. Eur J Med Chem 2016;116:13–26.
28. Perez GM, Salomon LA, Montero-Cabrera LA, et al.
Integrating sampling techniques and inverse virtual screen-
ing: Toward the discovery of artificial peptide-based recep-
tors for ligands. Mol Divers 2016;20:421–38.
29. Lauro G, Masullo M, Piacente S, et al. Inverse virtual screen-
ing allows the discovery of the biological activity of natural
compounds. Bioorg Med Chem 2012;20:3596–602.
30. Lauro G, Romano A, Riccio R, Bifulco G. Inverse virtual
screening of antitumor targets: Pilot study on a small data-
base of natural bioactive compounds. J Nat Prod 2011;74:
1401–7.
31. Tong YF, Zhang P, Chen F, et al. Synthesis and biological
evaluation of novel n-(alkoxyphenyl)-aminocarbonylbenzoic
acid derivatives as ptp1b inhibitors. Chinese Chemical
Letters 2010;21:1415–8.
32. Abdel-Aziz HA, Eldehna WM, Fares M, et al. Synthesis, bio-
logical evaluation and 2d-qsar study of halophenyl bis-
hydrazones as antimicrobial and antitubercular agents.
International Journal of Molecular Sciences 2015;16:8719–43.
33. Moldoveanu CC, Mangalagiu II. 4-methyl-and 4-(halophenyl)
pyrimidinium (4-halobenzoyl) methylides. Correlation of
structure, stability, reactivity, and biological activity.
Helvetica Chimica Acta 2005;88:2747–56.
34. Gonec T, Zadrazilova I, Nevin E, et al. Synthesis and bio-
logical evaluation of n-alkoxyphenyl-3-hydroxynaphthalene-
2-carboxanilides. Molecules 2015;20:9767–87.
35. Abad-Zapatero C, Metz JT. Ligand efficiency indices as guide-
posts for drug discovery. Drug Discov Today 2005;10:464–9.
36. Floresta G, Pistara V, Amata E, et al. Molecular modeling
studies of pseudouridine isoxazolidinyl nucleoside analogues
as potential inhibitors of the pseudouridine 5’-monophos-
phate glycosidase. Chem Biol Drug Des 2018;91:519–25.
37. Minoo P, Zlobec I, Baker K, et al. Prognostic significance of
mammalian sterile20-like kinase 1 in colorectal cancer. Mod
Pathol 2007;20:331–8.
38. de Souza PM, Lindsay MA. Mammalian sterile20-like kinase 1
and the regulation of apoptosis. Biochem Soc Trans 2004;32:
485–8.
39. Han S, Ren Y, He W, et al. Publisher correction: Erk-mediated
phosphorylation regulates sox10 sumoylation and targets
expression in mutant braf melanoma. Nat Commun 2018;9:
1404.
40. Han S, Ren Y, He W, et al. Erk-mediated phosphorylation
regulates sox10 sumoylation and targets expression in
mutant braf melanoma. Nat Commun 2018;9:28.
41. Boshuizen J, Koopman LA, Krijgsman O, et al. Cooperative
targeting of melanoma heterogeneity with an axl antibody-
drug conjugate and braf/mek inhibitors. Nat Med 2018;24:
203–12.
42. Lavoie H, Sahmi M, Maisonneuve P, et al. Mek drives braf
activation through allosteric control of ksr proteins. Nature
2018;554:549–53.
43. Wang Q, Ding W, Ding Y, et al. Homoharringtonine sup-
presses imatinib resistance via the bcl-6/p53 pathway in
chronic myeloid leukemia cell lines. Oncotarget 2017;8:
37594–604.
44. Jandl C, Liu SM, Canete PF, et al. Il-21 restricts t follicular
regulatory t cell proliferation through bcl-6 mediated inhib-
ition of responsiveness to il-2. Nat Commun 2017;8:14647.
45. Qian XL, Zhang J, Li PZ, et al. Dasatinib inhibits c-src phos-
phorylation and prevents the proliferation of triple-negative
breast cancer (tnbc) cells which overexpress syndecan-bind-
ing protein (sdcbp). PLoS One 2017;12:e0171169.
46. Zhang J, Wang S, Jiang B, et al. C-src phosphorylation and
activation of hexokinase promotes tumorigenesis and
metastasis. Nat Commun 2017;8:13732.
47. Pishvaian MJ, Slack RS, Jiang W, et al. A phase 2 study of
the parp inhibitor veliparib plus temozolomide in patients
with heavily pretreated metastatic colorectal cancer. Cancer
2018;124:2337–46.
48. Chen X, Huan X, Liu Q, et al. Design and synthesis of 2-
(4,5,6,7-tetrahydrothienopyridin-2-yl)-benzoimidazole carbox-
amides as novel orally efficacious poly(adp-ribose)polymer-
ase (parp) inhibitors. Eur J Med Chem 2018;145:389–403.
49. Langelier MF, Zandarashvili L, Aguiar PM, et al.
NADþ analog reveals PARP-1 substrate-blocking mechanism
and allosteric communication from catalytic center to DNA-
binding domains. Nat Commun 2018;9:844.
50. Lee JT, Li L, Brafford PA, et al. Plx4032, a potent inhibitor of
the b-raf v600e oncogene, selectively inhibits v600e-positive
melanomas. Pigment Cell Melanoma Res 2010;23:820–7.
51. Wu Z, Yan M, Hu SH, et al. Design, synthesis and biological
evaluation of indole derivatives as novel inhibitors targeting
b-raf kinase. Chin Chem Lett 2014;25:351–4.
52. Melnick A, Cerchietti LCA, Cardenas MG, et al. Bcl6 inhibitors
as anticancer agents in Bcl6 inhibitors as anticancer agents,
Google Patents; 2018.
53. Olgen S, Akaho E, Nebioglu D. Evaluation of indole esters as
inhibitors of p60(c-src) receptor tyrosine kinase and investi-
gation of the inhibition using receptor docking studies.
Journal of Enzyme Inhibition and Medicinal Chemistry 2003;
18:485–90.
54. Kilic¸ Z, Is¸g€or YG, Olgen S. Evaluation of new indole and bro-
moindole derivatives as pp60(c-src) tyrosine kinase inhibi-
tors. Chem Biol Drug Des 2009;74:397–404.
JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY 49
55. Cosi C. New inhibitors of poly(adpribose) polymerase and
their potential therapeutic targets. Expert Opinion on
Therapeutic Patents 2002;12:1047–71.
56. Ren L, Wenglowsky S, Miknis G, et al. Non-oxime inhibitors
of b-raf(v600e) kinase. Bioorg Med Chem Lett 2011;21:
1243–7.
57. Johannes JW, Almeida L, Daly K, et al. Discovery of az0108,
an orally bioavailable phthalazinone parp inhibitor that
blocks centrosome clustering. Bioorg Med Chem Lett 2015;
25:5743–7.
58. Thaimattam R, Daga PR, Banerjee R, Iqbal J. 3d-qsar studies
on c-src kinase inhibitors and docking analyses of a potent
dual kinase inhibitor of c-src and c-abl kinases. Bioorg Med
Chem 2005;13:4704–12.
59. Olesen SH, Zhu J-Y, Martin MP, Sch€onbrunn E. Discovery of
diverse small-molecule inhibitors of mammalian sterile20-
like Kinase 3 (MST3)). ChemMedChem 2016;11:1137–44.
60. Sander T, Freyss J, von Korff M, Rufener C. Datawarrior: An
open-source program for chemistry aware data visualization
and analysis. J Chem Inf Model 2015;55:460–73.
50 A. CILIBRIZZI ET AL.
